Chugai ( Chugai )


Chugai's picture

Chugai Pharmaceutical utilizes leading technologies in biopharmaceutical and molecular targeted drug discovery to create innovative drugs.

Chugai press release, blog etc

03/19/2018 - 23:45 Injection Syringe 12.5g Approved in Japan
03/15/2018 - 23:57 Chugai Starts Activities towards Commercialization of
01/31/2018 - 19:59 Further Improving Access to Therapies for Non-Small Cell Lung Cancer
01/19/2018 - 02:13 Chugai Obtains Approval of Humanized Anti-PD-L1 Monoclonal Antibody, TECENTRIQ
12/25/2017 - 19:52 The Launch of Chugais New Corporate Advertisement
12/20/2017 - 22:29 EU Follows US and Approves Chugais ALK Inhibitor "Alecensa " as First Line Therapy for ALK-Positive Non-Small Cell Lung Cancer
12/17/2017 - 22:16 Launch of the Photodynamic Diagnostic Agent "ALAGLIO Divided Granules 1.5g"
12/11/2017 - 00:24 Atezolizumab plus Avastin Significantly Improves Progression Free Survival Compared with Sunitinib in PD-L1 Positive Patients for the First-line Treatment of Advanced Renal Cell Carcinoma in the IMmotion151 Study
12/07/2017 - 02:45 Chugais Emicizumab Every Four Weeks Showed Positive Interim Results
11/29/2017 - 02:33 TWOCELLS and Chugai Announce Performing Surgery of the First Patient in Phase III Trial for gMSC
11/21/2017 - 03:16 Immune Checkpoint Inhibitor Atezolizumab Significantly Improves Progression Free Survival in Patients with Non-Small Cell Lung Cancer Compared with Chemotherapy in the IMpower150 Study
11/19/2017 - 23:45 Meets Primary Endpoint in Phase III Study
11/13/2017 - 22:56 Notice Concerning Execution of Asset Transfer of 13 Long-Term Listed Products from Chugai to Taiyo Pharma
11/08/2017 - 04:55 Chugai's ALK Inhibitor "Alecensa " Approved for the Treatment of First Line Therapy on ALK-Positive Non-Small Cell Lung Cancer in the US
11/07/2017 - 03:13 "AYAs Life," a Website for Young Cancer Patients and Their Families, Undergoes Major Upgrade
11/05/2017 - 23:15 Eldecalcitol, an Active Vitamin D 3 Derivative, Increases Bone Mineral Density of Osteoporosis Patients in Chinese Phase III Study
11/01/2017 - 21:03 New Data of Emicizumab Presented
10/25/2017 - 02:29 Filed for Additional Indication of Adjuvant Therapy for HER2-Positive Early Breast Cancer